Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma

BACKGROUND: Most patients with multiple myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients’ bone marrow (BM) and immunotherapeutic approaches could contribute to eradicating...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousef, Sara, Heise, Johanna, Lajmi, Nesrine, Bartels, Katrin, Kröger, Nicolaus, Luetkens, Tim, Atanackovic, Djordje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474344/
https://www.ncbi.nlm.nih.gov/pubmed/26088750
http://dx.doi.org/10.1186/s12967-015-0562-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474344/
https://www.ncbi.nlm.nih.gov/pubmed/26088750
http://dx.doi.org/10.1186/s12967-015-0562-5

Ejemplares similares